Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matinas BioPharma (MTNB)
NYSE MKT:MTNB
Holding MTNB?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.78Last Year’s EPS
-$1Same Quarter Last Year
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 2.91%
|Next Earnings Date:Mar 18, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture, with notable progress in MAT2203 licensing and financial management, counterbalanced by the lack of revenue, delays in trial timelines, and challenges in oncology trials. The sentiment is cautiously optimistic but acknowledges the hurdles that need addressing.Company Guidance
During the Matinas BioPharma Q2 2024 earnings call, several key metrics and guidance updates were provided. The company reported a net loss of $5.7 million or $0.02 per share for the quarter, a slight improvement from the $6.1 million or $0.03 per share loss in the same period of 2023. Total costs and expenses decreased to $5.8 million from $6.2 million year-over-year, primarily due to reduced clinical development and administrative costs. Matinas did not report any revenue for the quarter, consistent with the previous year. Cash, cash equivalents, and marketable securities stood at $14.3 million as of June 30, 2024, an increase from $13.8 million at the end of 2023, bolstered by $10 million in gross proceeds from a registered direct offering. The company is advancing plans for the ORALTO Phase III trial for MAT2203, with ongoing preparations and a potential start in the fourth quarter of 2024. Additionally, Matinas has signed a nonbinding term sheet for the global rights to develop, manufacture, and commercialize MAT2203, with the final agreement potentially including upfront payments, development and commercial milestones, and royalties.MAT2203 Licensing Progress
Matinas BioPharma has signed a nonbinding term sheet for the licensing of global rights to develop, manufacture, and commercialize MAT2203, indicating potential future growth and collaborations.
Compassionate/Expanded Use Access Program Success
Since June 24, 7 additional patients accessed MAT2203, bringing total enrollment to 31. Out of 15 patients who completed treatment, 8 had a complete response, and 7 were dramatically improved.
Reduced Financial Losses
The net loss for Q2 2024 was $5.7 million or $0.02 per share, compared to a net loss of $6.1 million or $0.03 per share in Q2 2023.
Increased Cash Reserves
Cash, cash equivalents, and marketable securities increased to $14.3 million as of June 30, 2024, from $13.8 million as of December 31, 2023, due to a $10 million direct offering.
---
MTNB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MTNB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $0.55 | $0.53 | -3.64% |
| Aug 14, 2024 | $7.85 | $7.65 | -2.55% |
| May 09, 2024 | $8.84 | $8.78 | -0.68% |
| Mar 27, 2024 | $14.50 | $13.55 | -6.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Matinas BioPharma (MTNB) report earnings?
Matinas BioPharma (MTNB) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Matinas BioPharma (MTNB) earnings time?
Matinas BioPharma (MTNB) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MTNB EPS forecast?
MTNB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.78.
---